IRVINE, Calif., June 24, 2025 /PRNewswire/ -- Zymo Research stole the spotlight at the American Society for Microbiology (ASM) Microbe 2025 conference with the official...
Latest Research Demonstrates Promising Improved Glucose Homeostasis by Reprogramming Alpha Cells
AUSTIN, Texas, June 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a...
Study is the first to explore the impact of genetic ancestry on tumor genomics in T-ALL
PHILADELPHIA and MEMPHIS, Tenn., June 24, 2025 /PRNewswire/ --...
SEOUL, South Korea, June 23, 2025 /PRNewswire/ -- Novogene, a global leader in next-generation sequencing (NGS) and multi-omics solutions, today announced the establishment of...
PARIS, FRANCE, 20 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This recommendation is based on results from the CABINET Phase III trial presented at the European Society of Medical Oncology (ESMO) Congress 2024 and published in the New England Journal of Medicine.3,4 A final decision on the approval in the European Union is expected in the coming months.
BEIJING, June 20, 2025 /PRNewswire/ -- Gene Solutions announces the signing of two strategic Memoranda of Understanding (MOUs) with ZaoDx and Xiong'an MagicBiotech Co., Ltd....
SHENZHEN, China, June 20, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation...
Lilly Collaboration Accelerates RyboDyn's Dark Proteome Targets Toward First-in-Class Therapies
SAN DIEGO, June 19, 2025 /PRNewswire/ -- RyboDyn, Inc., a biotechnology company pioneering first-in-class immunotherapies...
IRVINE, Calif., June 18, 2025 /PRNewswire/ -- As research and diagnostic companies grapple with rising prices and persistent backorders from offshore suppliers, Zymo Research is...
Hoag is the first hospital in the United States to offer a comprehensive on-site program for pioneering esophageal precancer detection tool, EsoGuardEsoGuard addresses patient...
The Oligonucleotide Synthesis Market is poised for robust growth, fueled by advancements in personalized medicine, molecular diagnostics, and genomics research. However, high production costs, regulatory...
Updated Resource, High-Grade Discovery, and Accelerated De-risking Underscore Fisher East's Strategic Value in the Global Critical Materials Supply Chain
TORONTO and PERTH, Australia, June 18,...
Updated Resource, High-Grade Discovery, and Accelerated De-risking Underscore Fisher East's Strategic Value in the Global Critical Materials Supply Chain
TORONTO and PERTH, Australia, June 18,...